BiotechTube
EydisBio

EydisBio

Cambridge, United States· Est.
eydisbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2020 and based in Durham, North Carolina, EydisBio is a private biotech startup focused on addressing high unmet medical needs in autoimmunity and inflammation. The company's core innovation is its UPCP chemoproteomics platform, which enables the discovery of intrinsically selective kinase inhibitors, aiming to improve therapeutic outcomes and developmental success rates. Led by a founder with a successful track record of company creation and drug development, EydisBio is advancing its lead TAK1 inhibitor candidate through in vivo efficacy and pilot safety studies.

Autoimmune DiseasesInflammatory DiseasesChronic PainFibrotic Diseases

Technology Platform

The Universal Purinome Capture Platform (UPCP) is a chemoproteomics platform that screens chemical scaffolds against the entire human 'purinome' (kinases and other ATP-binding proteins) to identify intrinsically selective kinase inhibitors early in the discovery process.

Opportunities

The significant unmet need in autoimmune diseases, particularly for patients failing anti-TNF therapies, presents a large addressable market.
Success with EYD-001 could validate the UPCP platform, enabling rapid expansion into other kinase targets in inflammation and oncology.
The oral, small molecule format offers potential convenience and cost advantages over biologics.

Risk Factors

The company is at a high-risk, preclinical stage with no disclosed funding, creating uncertainty about its financial runway.
The novel TAK1 target, while promising, carries biological risk for efficacy and safety.
The company faces competition from larger, well-funded entities also pursuing kinase inhibitors in inflammation.

Competitive Landscape

EydisBio competes in the emerging field of TAK1 inhibition against research programs at large pharma and biotech firms. Its primary differentiation is the high selectivity of its compounds, enabled by the UPCP platform, aiming to avoid the off-target toxicity that has limited earlier kinase inhibitors. It also differentiates from injectable anti-TNF biologics by pursuing an oral therapy.

More companies in Small Molecule Drugs →More companies in United States →